Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 809-818

  Walthour, Amy ^a   Seymour, Lynne ^b   Tackett, Randall ^b   Perri, Matthew ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Atypical antipsychotic; Health care utilization; Prior authorization; Segmented regression analysis; Time series analysis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; AUTISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; DEPRESSION; EMERGENCY WARD; FEMALE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MEDICAID; MIXED MANIA AND DEPRESSION; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; GEORGIA; GOVERNMENT PROGRAMS; HEALTH SERVICES; HUMANS; MALE; MEDICAID; MENTAL HEALTH SERVICES; MIDDLE AGED; PROGRAM EVALUATION; REGRESSION ANALYSIS; REIMBURSEMENT MECHANISMS; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 77951572313     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M620     Document Type: Article

References (17)

1. The National Institute of Mental Health. www.nimh.nih.gov/health/topics/ schizophrenia/index.shtml (accessed 2009 Jun 4).
2. US Food and Drug Administration. Drug approval reports by month. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ (accessed 2009 Sep 16).
3. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff 2005;24:195-205.
4. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior-authorization on second-generation antipsychotic agents on pharmacy utilization and reimbursement. Psychiatr Serv 2008;59:540-546
5. Frank RG, Conti RM, Goldman HH. Mental health policy and psychotropic drugs. Milbank Q 2005;83:271-298
6. Dubberly J, Perri M, Lorys R, Walthour AE. Cost control in mental health. Presented at: 12th International Meeting. International Society for Pharmaceutical Outcomes Research, Arlington, VA, May 21, 2007.
7. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharmacol Ther 2002;27:299-309.
8. SAS Institute Inc., SAS OnlineDoc, Version 8, Cary, NC: SAS Institute Inc., 2000.
9. McCombs JS, Mulani P, Gibson PJ. Open access to innovative drugs: treatment substitutions or treatment expansion? Health Care Financ Rev 2005;25:35-53.
10. West JC, Wilk JE, Muszynski IL, et al. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first four months of the Medicare prescription drug benefit. Am J Psych 2007;164:789-796
11. Wilk JE, West JC, Rae DS, et al. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiat Serv 2008;59:34-39
12. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff 2008;27:185-195
13. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. 2006. Psychiat Serv 2006;57:127-129
14. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23:135-146
15. The MaineCare Advisory Committee's Prior Authorization Subcommittee report and recommendations on prior authorization for prescription drugs in the MaineCare and Drugs for the Elderly Programs. Maine Department of Health and Human Services. January 19, 2005.
16. Tunis SL, Ascher-Svanum H, Stensalnd M, Kinon BL. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics 2004;22:1-18.
17. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18.